Myoepithelial Cells May Be Key to Suppression of DCIS Growth

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 4
Volume 6
Issue 4

LOS ANGELES--Laboratory studies from the UCLA School of Medicine point to a role for myoepithelial cells in suppressing breast cancer invasion, said researcher Mark Sternlicht, PhD. Myo-epithelial cells lie between the epithelium and the basement membrane. They synthesize and maintain the basement membrane and can promote epithelial differentiation. They are found surrounding benign and nonmalignant lesions.

LOS ANGELES--Laboratory studies from the UCLA School of Medicine pointto a role for myoepithelial cells in suppressing breast cancer invasion,said researcher Mark Sternlicht, PhD. Myo-epithelial cells lie betweenthe epithelium and the basement membrane. They synthesize and maintainthe basement membrane and can promote epithelial differentiation. Theyare found surrounding benign and nonmalignant lesions.

"Myoepithelial cells rarely transform," Dr. Sternlicht saidat the San Antonio Breast Cancer Symposium. "And when they do, theytransform to benignity or low-grade neoplasms that do not invade and donot metastasize."

Surrogates Developed

Researchers at the UCLA laboratory, under the direction of Dr. SanfordBarsky, have developed cell lines and transplantable xenografts from benignmyoepithe-lial tumors to serve as a surrogate to study the effects of myoepithelialcells on breast cancer invasion.

"These myoepithelial tumors are slow growing; it takes six monthsof nude mouse growth to reach about 1.5 cm in diameter," Dr. Sternlichtsaid. He noted that these tumors make an abundant extracellular matrix,composed of a number of basement membrane and non-basement membrane molecules.

More importantly, he said, myoepithe-lial cells express high levelsof proteinase inhibitors and angiogenic inhibitors, and very low levelsof proteinase and no angiogenic-stimulating factors. Many of these proteinaseand angiogenic inhibitors can be seen selectively in tissue sections ofductal carcinoma in situ (DCIS) in the surrounding myoepithelial layer.

One of the myoepithelial cell lines, HMS1, has been shown in vitro todramatically inhibit tumor invasion and angiogenesis (endothelial cellmigration and mitogenesis). The UCLA work further suggests that the anti-invasiveeffect is mediated in part through maspin, a member of the serpin superfamilyof proteinase inhibitors, while the angiogenic inhibition is mediated primarilythrough thrombospondin-1.

With all of this evidence for the "myoepithelial defense,"Dr. Sternlicht hypothesizes that DCIS is regulated by the paracrine interactionof the myoepi-thelial cells and "this is why DCIS stays confined forso many years and why there is no demonstrable genetic alteration betweenDCIS and invasive cancer."

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content